← Passage Bio overview

Passage Bio vs Biogen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Passage Bio Inc (PASG)

Biogen Inc (BIIB)

Q3 2026
▼3▲1

Biogen's mixed quarter: Leqembi approvals offset trial miss and guidance cut

  • Leqembi approvals expand access The FDA approved at-home subcutaneous Leqembi, and China and Japan approved injections, making the Alzheimer's drug easier to use. Leqembi sales rose 15% to about $184 million, helping Q2 results beat expectations.

    This is a key positive development that drove investor optimism and revenue growth.

  • Diranersen trial failure Biogen's experimental drug diranersen missed its main trial goal, causing shares to drop 9%. This setback raised concerns about the company's pipeline and future growth prospects.

    This was a major negative event that directly impacted the stock price.

  • Guidance cut on acquisition charges Biogen cut its 2026 earnings guidance to $12–$13 per share due to about $3.85 per share in acquisition charges, including from the $5.6 billion Apellis buyout. This lowered profit expectations.

    The guidance cut is a significant negative factor that weighed on the stock.

  • Medicare pricing pressure on ZURZUVAE Medicare pricing pressure may limit the launch of ZURZUVAE, and Biogen is restricting it to a few European countries. This could slow the drug's uptake and revenue potential.

    This highlights a regulatory and pricing challenge that could hinder growth.

August 2026
▲3▼1

Biogen expands Alzheimer's reach but pricing and competition weigh

  • RayThera acquisition adds immunology drug Biogen acquired RayThera, gaining an early-stage immunology drug. This adds a new potential treatment to its pipeline, showing progress in building future growth beyond its current medicines.

    New acquisition expands pipeline, a key positive development in the period.

  • China and Japan approve at-home Leqembi injections China and Japan approved at-home under-the-skin Leqembi injections, making Alzheimer's treatment easier and expanding the market. This could boost sales and patient access in key regions.

    Geographic expansion of Leqembi is a new positive catalyst for demand.

  • Ten Phase 3 programs promise growth Biogen has ten late-stage programs in development, which could drive future growth as its multiple sclerosis revenue shrinks. This shows a strong pipeline to replace older products.

    Pipeline strength is a forward-looking positive not previously highlighted.

  • Medicare pricing pressure may limit ZURZUVAE launch Medicare pricing pressure could hurt the launch of ZURZUVAE, and Biogen is limiting it to a few European countries. This adds risk to a key new product's sales potential.

    New pricing and launch risk for ZURZUVAE is a negative factor.

Latest
▲3▼1

Biogen's pipeline push and Leqembi rollout drive gains, but pricing risks loom

  • 10 Phase III programs signal growth beyond MS Biogen said it has 10 late-stage trials with results starting in Q4, shifting focus from its shrinking MS business to new drugs like LEQEMBI and ZURZUVAE. This raises hopes for future revenue growth, supporting the stock.

    This is the main new strategic update that could drive long-term growth and investor optimism.

  • Japan approves at-home Leqembi injection Japan cleared a subcutaneous form of Leqembi, allowing weekly at-home dosing instead of hospital infusions. This is the third country to approve it, making the Alzheimer's drug easier to use and expanding its market, which could boost sales.

    New regulatory approval directly expands the addressable market for a key growth drug.

  • Medicare price crackdown may limit Zurzuvae launch A study warns that U.S. efforts to align Medicare drug prices with cheaper countries could push companies to raise prices or withdraw medicines elsewhere. Biogen's CEO said Zurzuvae will launch in only a few European countries to offset lost U.S. revenue, signaling a hit to its global sales potential.

    This is a new regulatory risk that could reduce future revenue from a key product.

  • Biogen posts best quarterly revenue beat in group Biogen's Q2 revenue of $2.74 billion rose 3.4% and beat expectations by 12.1%, the strongest among 11 therapeutics stocks. This shows better-than-expected commercial execution, which can lift investor confidence.

    New earnings data confirms strong performance relative to peers, a positive fundamental signal.

▲3

Biogen's mixed quarter: raised revenue, cut EPS, new China approval

  • RayThera acquisition closes, EPS guidance cut Biogen completed its purchase of RayThera, adding an early-stage immunology drug. But acquisition charges forced it to slash 2026 adjusted EPS guidance to $12–$13 from $14.25–$15.25. The revenue outlook rose to mid-single-digit growth, but the profit hit is what investors will feel near-term.

    This is the single biggest new event, directly changing Biogen's earnings outlook and explaining the stock's mixed reaction.

  • China approves at-home LEQEMBI injection China approved a subcutaneous (under-the-skin) form of LEQEMBI for early Alzheimer's, allowing weekly at-home dosing instead of hospital infusions. This is the second country to clear it, after the U.S. in July. It widens the market and makes treatment far easier for patients.

    A new regulatory approval in a huge market (17 million early Alzheimer's patients in China) directly boosts the long-term sales potential of Biogen's key Alzheimer's drug.

  • Five Phase 3 readouts ahead; shares seen as undervalued Biogen raised its non-GAAP EPS guidance and has five late-stage trial results coming in lupus, transplant and rare diseases. Shares trade about 10% below the average analyst target, with a 54% one-year total return. But competition in MS and Alzheimer's, plus launch risks for LEQEMBI and ZURZUVAE, remain real concerns.

    This gives the forward-looking catalyst picture and the valuation gap, which is central to why investors are watching Biogen now.

  • Biogen adopts Veeva's AI-powered CRM globally Biogen selected Veeva's Vault CRM suite, an AI-driven sales and safety platform, for global use. This is an operational upgrade, not a direct revenue driver, but it signals Biogen is investing in modern commercial infrastructure. It also deepens a multi-year software relationship, which can lower long-term selling costs.

    It shows Biogen is modernizing its commercial operations with AI, a modest but real positive for efficiency and execution.

July 2026
▲2▼2

Biogen's mixed July: Leqembi wins, diranersen disappoints, guidance cut

  • FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, an at-home under-the-skin version of Biogen's Alzheimer's drug. This should make treatment easier and more convenient, potentially boosting demand and future sales.

    This is a new regulatory approval that could drive future revenue growth.

  • Q2 results beat on rare-disease and Leqembi demand Biogen's second-quarter results beat expectations, helped by strong demand for rare-disease drugs and Leqembi, with Leqembi sales up 15% to about $184 million. This shows the company's newer products are gaining traction.

    This is new financial data showing better-than-expected performance.

  • Diranersen trial misses goal, shares drop 9% Biogen's experimental Alzheimer's drug diranersen missed its main trial goal, with a puzzling result: the lowest dose worked best while higher doses did worse. The failure sent shares down about 9%.

    This is a major clinical setback that directly hurt the stock.

  • 2026 earnings guidance cut on acquisition charges Biogen lowered its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, due to about $3.85 per share in acquisition charges, including 85 cents from the $5.6 billion Apellis buyout.

    This is a new guidance cut that weighs on investor expectations.

▲3▼1

Biogen beats on drug demand but cuts 2026 profit outlook

  • Q2 beat on rare-disease and Leqembi demand Biogen's second-quarter profit and revenue beat expectations, helped by strong sales of rare-disease medicines and a 15% rise in Leqembi sales to about $184 million. This shows the core business is growing, which supports the stock.

    This is the main new event of the period and directly explains why Biogen is moving.

  • 2026 profit guidance cut on Apellis charges Biogen slashed its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, largely due to $3.85 per share of acquisition-related charges, including 85 cents from the $5.6 billion Apellis buyout. This weighs on the stock.

    This is the key counterweight that explains why the stock isn't rising more despite the earnings beat.

  • Leqembi real-world data and sales momentum A real-world study showed over 75% of early Alzheimer's patients remained stable on Leqembi, and Q2 sales grew 43% excluding one-time stockpiling. This supports adoption and future sales, a positive for Biogen as Eisai's partner.

    This new evidence reinforces the commercial case for Biogen's key Alzheimer's drug.

  • Pipeline progress: Gazyva priority review, litifilimab enrollment The FDA granted priority review to Gazyva for a rare kidney disease, and Biogen's lupus drug litifilimab completed Phase III enrollment with results due in H2 2026. These advance the pipeline and offer future growth, supporting the stock.

    These are new regulatory and clinical milestones that add to the long-term growth story.

▲3▼1

Leqembi at-home approval lifts Biogen, but diranersen dosing flaw triggers sell-off

  • FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, a once-weekly under-the-skin injection for early Alzheimer's, allowing at-home dosing. This removes the need for IV infusions, which should boost patient demand and sales. Biogen shares rose on the news.

    This is a major new approval that directly expands the market for Biogen's key Alzheimer's drug.

  • Diranersen shows 42% cognitive decline slowdown Biogen presented Phase 2 data showing its tau-targeting drug diranersen slowed cognitive decline by 42% on one measure and cut tau tangles. This suggests a potential new Alzheimer's treatment, lifting hopes for future growth.

    Positive efficacy data from a new drug candidate is a key driver of investor optimism.

  • Dosing paradox clouds diranersen data, stock tumbles The same Phase 2 trial missed its main goal because the lowest dose worked best while higher doses did worse. This unexplained 'dosing paradox' raised doubts about the drug's effectiveness and path forward, causing Biogen shares to fall nearly 9%.

    This negative twist directly caused a sharp sell-off and creates uncertainty about a key pipeline asset.

  • Truist upgrade highlights Alzheimer's pipeline A Truist analyst upgrade pointed to optimism for Biogen's Alzheimer's pipeline, helping the stock gain even as the broader market fell. This analyst view reinforced positive sentiment around the company's Alzheimer's efforts.

    Analyst upgrade is a fresh catalyst that supported the stock price during the period.

Q2 2026
▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

  • RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

    This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

  • FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

    This is a new regulatory win that supports the bull case for Biogen's pipeline.

  • Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

    This is a new negative event that introduces regulatory and legal uncertainty.

  • Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

    This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

June 2026
▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

  • RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

    This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

  • FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

    This is a new regulatory win that supports the bull case for Biogen's pipeline.

  • Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

    This is a new negative event that introduces regulatory and legal uncertainty.

  • Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

    This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

  • RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.

    This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.

  • FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.

    This is a new regulatory win that supports the bull case for Biogen's pipeline.

  • Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.

    This is a new negative event that introduces regulatory and legal uncertainty.

  • Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.

    This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

© 2026 MarketDXWhy